Figure 2.

The PPARδ antagonist inhibited the anti-depression-like action of telmisartan in mice receiving UCMS. The PPARδ antagonist, GSK0660 (5 nmol.L⁻¹, i.c.v), was administered 30 min before telmisartan treatment. In the open field test, the animals were allowed to explore the open field arena for 5 min. (A) the total distance travelled; (B) the time spent in the central; (C) frequency of grooming; (D) frequency of rearing; (E) the percentage of sucrose solution consumed (%) in the sucrose preference test (SPT); (F) PPARδ expression levels in the hippocampus of the various treatment groups; (G) 5-HTT expression levels in the hippocampus of the various treatment groups. Data are presented as the mean ± SEM (n = 8 per group). *p < 0.05 and **p < 0.01 compared to the corresponding control; ^#p < 0.05 and ^##p < 0.01 compared to the UCMS group. Full-length blots are presented in Supplementary Fig. S2.